Infectious Diseases Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin). However, since the latter is administered as a prodrug, there are major pharmacokinetic differences between both polymyxins that may potentially determine different clinical and microbiological outcomes. Studies addressing clinical or microbiological outcomes in patients treated with polymyxin B for MDR or XDR GNB are reviewed in this chapter.
多黏菌素 B 是另一种临床可用的多黏菌素，它在临床实践中重新出现，用于治疗由多药（MDR）或广泛耐药（XDR）革兰氏阴性菌（GNB）引起的感染。它的化学结构与多黏菌素 E（黏菌素）非常相似。然而，由于后者作为前药给药，因此两种多黏菌素之间存在主要的药代动力学差异，这可能潜在地决定不同的临床和微生物学结果。本章综述了用于治疗 MDR 或 XDR GNB 的多黏菌素 B 的患者的临床或微生物学结果的研究。
